It is well established that selective COX-2 inhibitors exhibit potent effects against progression of select solid tumours. However, their effects on liquid tumours have not been fully established. By taking advantage of murine Friend Disease we have shown a strong antileukemic effect of celecoxib by determining novel in vitro targets. Western blot analyses revealed the expression of COX-2 in a panel of Friend Virus-transformed, splenic-derived primary erythroleukemic blasts and established cell lines generated in our laboratory. We have shown that celecoxib at concentrations as low as 20 lM significantly suppresses proliferation of the selected murine erythroleukemia cell line HB60-5. The greatest proliferative inhibition was seen at 40 lM of celecoxib, resulting in apoptosis. Our results also demonstrate that treatment of the established murine erythroleukemia cell line HB60-5 with celecoxib results in suppression of c-Kit and erythropoietin receptor (Epo-R) phosphorylation resulting in apoptosis, likely through decreased levels of survival factors. However, upon overexpression of c-Kit alone in these cells a significant increase in survival and twofold increase in proliferation in the presence of celecoxib were observed (Po0.05). Finally, since responsiveness of our murine erythroleukemia cell lines to celecoxib is above the reported physiologically achievable levels in vivo, we have provided in vitro evidence to suggest that reduced sensitivity of erythroleukemic cells to lower doses of celecoxib may be a consequence of the loss of wild-type p53. These findings are pivotal in addressing potential discrepancies associated with sensitivity of murine erythroleukemic cells to celecoxib in vitro versus in vivo.
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Introduction
Initial studies implicating the pathological role of prostaglandins during cancer development originally stemmed from those of colorectal carcinogenesis, correlating an overproduction of prostaglandins with increasing proliferative and motile capacities of these cancerous cells (Tsujii and DuBois, 1995; Tsujii et al., 1997) . To further understand the contributions of prostaglandins to cancer development considerable emphasis has been placed on the enzymes catalyzing their production. The cyclooxygenases are comprised of two main isoforms, cyclooxygenase-1 and -2, commonly referred to as COX-1 and -2. While COX-1 is constitutively expressed and required for tissue-specific maintenance, the COX-2 isoform is induced during inflammation. This enzymatic upregulation is responsible for the increased conversion of arachadonic acid to an endoperoxide intermediate, leading to PGH 2 overproduction and subsequent conversion to prostaglandins PGD 2 , PGE 2 , PGF 2 a, PGI 2 and TxA 2 . In addition to colon carcinogenesis, screening of various cancers including breast (Hwang et al., 1998) , head and neck (Chan et al., 1999) , and esophagus (Shamma et al., 2000) have implicated COX-2 upregulation and activity in disease progression.
A novel class of nonsteroidal antiinflammatory drugs (NSAIDs) has recently emerged which specifically target COX-2. Targeting COX-2 has shown considerable efficacy as a potential therapy in treating cancers overexpressing this isoform. This has been recently demonstrated in numerous cancer models including UVinduced skin tumours in SKH : HR-1-hrBr hairless mice (Fischer et al., 1999) , colorectal carcinogenesis in Apc Min mice (Beazer-Barclay et al., 1996) , and 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in female Sprague Dawley rats (Harris et al., 2000) . In addition, tumour development has been shown to be significantly impaired if signaling pathways involving both COX-2 expression and epidermal growth factor (EGF) activation are simultaneously inhibited (Torrance et al., 2000) .
While selective COX-2 inhibitors have shown to mediate anticancer effects via inhibition of this enzyme in the aforementioned studies, many well-established in vitro models have also demonstrated significant antiproliferative, pro-apoptotic capabilities of these inhibitors in a COX-2-independent manner. Human prostate LNCaP and PC-3 cancer cells, for example, exhibit sensitivity towards non-selective COX inhibitors through a pro-apoptotic mechanism irreversible even in the presence of increased bcl-2 (Lim et al., 1999) . In addition, the pro-apoptotic protein Bax has been shown to induce apoptosis in colorectal cancer cells upon inhibition of the antiapoptotic protein bcl-X L expression in the presence of NSAIDs (Zhang et al., 2000) . Thus, a mere shift between pro-and antiapoptotic factors in the presence of NSAIDs, leading to death of cancer cells, would suggest other potential in vitro targets of selective COX-2 inhibitors, which remain elusive.
With respect to the progression of liquid tumours, there is currently little evidence to suggest a potential mechanism by which COX-2 inhibitors may mediate their effects on leukemic progression in vivo. A single study has recently reported in vitro suppression of both proliferation and differentiation of human leukemic cell lines, U-937 and ML-1, in the presence of the COX-2-specific inhibitor NS-398 (Nakanishi et al., 2001) . The authors of this study were also able to induce cell-cycle arrest in the presence of NS-398 and nabumetone.
In this study we have utilized murine erythroleukemia cell lines with well-characterized genetic changes, derived from mice with Friend Disease to determine their in vitro responsiveness to celecoxib. In the past two decades, we and others have demonstrated that the induction of erythroleukemias by Friend Murine Leukemia Virus (F-MuLV) is associated with the activation of the transcription factor, Fli-1 (Howard et al., 1996) . Later events associated with progression of Friend Disease are inactivation of the tumour suppressor gene p53 (Ben-David et al., 1990) and activation of the antiapoptotic factor Bcl-2 (Howard et al., 2001) . We have shown expression of COX-2 in several Friend Virus-induced tumours as well as established cell lines. Treatment of a well characterized erythroleukemia cell line, HB60-5, with celecoxib resulted in potent antiproliferative and pro-apoptotic responses at concentrations exceeding 20 mM, closely recapitulating the effects observed by others using various cancer models. Furthermore, in our model celecoxib-mediated apoptosis was associated with a significant decrease in c-Kit and Epo receptor phosphorylation, although overexpression of c-Kit alone was associated with increased survival and proliferation in the presence of the drug. With respect to effective dose responses to celecoxib between in vitro versus in vivo settings, the former achievable in the presence of several fold increases of drug, we provide evidence that the wild-type status of p53 in our murine erythroleukemia model not only correlates with COX-2 expression, but is also a pertinent factor in mediating sensitivity towards celecoxib.
Results

COX-2 expression in Friend Virus-transformed leukemic tissue and erythroleukemia cell lines
To establish the expression of COX-2 in Friend Virustransformed tumours, in-house derived primary tumours and cell lines were analyzed via Western blot analysis. COX-2 expression was observed in primary spleen cells isolated from mice infected with Friend Viruses FVP and F-MuLV and designated 12F (FMuLV), FVP-12 (FVP) and HB26-4b (F-MuLV), and also in the established F-MuLV-transformed cell lines HB60-5, CB7 and CB3. DP16-1 is a derivative of FVPtransformed cells (Figure 1 ). With the exception of the HB60-5 cell line, the level of COX-2 expression was markedly higher in primary leukemic tissues derived from whole spleens than the immortalized cell lines (see Discussion). These results confirm the expression of COX-2 in Friend Virus-transformed erythroblasts.
Celecoxib suppresses the proliferation of HB60-5 erythroleukemic cells and induces apoptosis
To determine the effective response of erythroleukemic cells to the selective COX-2 inhibitor, celecoxib, the SCF and Epo-dependent HB60-5 cells were grown over a period of 72 h in the presence or absence of varying concentrations of drug. Concentrations below 10 mM were found to have very little effect on proliferating cells, while a significant antiproliferative effect was evident at concentrations at, or exceeding 20 mM (Figure 2 , Panels a-c) (Po0.05). Similarly, this effect was also observed in two other murine erythroleukemia cell lines CB3 and CB7 (data not shown). It has previously been reported that EtOH, at low concentrations, can stimulate the growth of cells (Sachinidis et al., 1999) . Since celecoxib is reconstituted in EtOH, the increase in proliferation detected in HB60-5 cells treated with EtOH alone is an expected response, although by an undetermined mechanism. To assess whether the reduction in cell number was due to increased apoptosis, HB60-5 cells were treated with celecoxib or vehicle alone and genomic DNA was extracted and analyzed for laddering, a hallmark of apoptosis. At 40 mM of celecoxib, DNA laddering was observed, but not in the EtOH treated cells (Figure 3 ). Concentrations greater than 40 mM (i.e. 50 and 60 mM) also resulted in increased DNA laddering, not evident however in the presence of equivalent volume of ethanol vehicle alone. Since DNA laddering was not evident at a concentration of 20 mM celecoxib (data not shown), it is suggestive that while no cell death is mediated at this concentration, it does have a significant impact on the proliferation of these cells. These effects were also observed when tested on human erythroleukemia cell lines K562 and Hel (data not shown).
Inhibition of c-Kit and Epo-R phosphorylation by celecoxib
To identify the potential mechanism by which celecoxib induces apoptosis in HB60-5 cells, we examined pathways known to be involved with mediating survival signals in murine erythroleukemic cells. Considerable evidence has been previously provided regarding the induced cell death of selected cancer cells in the presence of COX-2 inhibitors, independent of COX-2 inhibition. Given the pivotal role played by c-Kit and Epo-R in cell survival of HB60-5 (Tamir et al., 1999) , it was decided to investigate the functional status of these receptors in the presence of celecoxib at concentrations that mediated their death in vitro. Upon immunoprecipitation of both receptors and analysis of their phosphorylation status, it was observed that pre-incubation of HB60-5 cells in the presence of 40 mM celecoxib for one hour resulted in complete abrogation of phosphorylation for both receptors (Figure 4a and b). The suppression of the c-kit and Epo receptors was not seen in HB60-5 cells treated with EtOH alone. Since the removal of both Epo and SCF from the culture medium of HB60-5 cells will (Tamir et al., 1999) , the death induced by celecoxib on this cell line in vitro is likely due to a block in the signaling cascade downstream of these receptors.
Overexpression of c-Kit overcomes celecoxib-induced cell death in HB60-5 cells
As it has been shown that viability of HB60-5 erythroleukemic cells requires functional c-Kit and Epo receptors, and that abrogating phosphorylation of these receptors by celecoxib leads to apoptosis, the question was then asked whether overexpressing either receptor could render these cells more resistant to celecoxib-induced death. Although both SCF and Epo are required for the survival of this cell line, it was decided to focus on c-Kit receptor since its function is pivotal in proliferation of HB60-5 (Tamir et al., 1999) . Thus, cells were infected with viral vectors encoding a constitutively active form of c-Kit (c-Kit þ ) or vector control (LXS-N). When grown in the presence of SCF alone, the viability of HB60-5/c-Kit þ cells was maintained over a three-day period, although only moderate proliferation was observed. However, HB6-5/LXS-N control cells revealed significant mortality within a 24 h period with no evidence of recovery (Po0.05) (Figure 5a ). These cells were then subjected to stimulation experiments including celecoxib or vehicle control as previously outlined and their growth kinetics were monitored over a 3 day period. As observed before, ethanol stimulated cell proliferation in both HB60-5/cKit þ and /LXS-N cells, albeit to a greater extent in cKit þ cells (Figure 5b ). However, in the presence of 40 mM celecoxib a significant increase in survival and proliferation of HB60-5/c-Kit þ over /LXS-N (Po0.05) was observed ( Figure 5b ). To further support these results, immunoprecipitation analysis carried out in similar fashion as previously described revealed that HB60-5/c-Kit þ cells exhibited increased tyrosine phosphorylation on c-Kit in the presence of SCF and celecoxib when compared to HB60-5/LXS-N cells ( Figure 5c ). It is important to mention that although the transformed cells exhibit constitutive active c-Kit, due to a low number of phosphorylated sites, the receptor remains undetectable by immunoblotting methods in the absence of SCF, as in non-transformed controls.
Loss of p53 in erythroleukemic cells reduces sensitivity to celecoxib
We have previously demonstrated that mutations within the p53 gene have been detected in immortalized erythroleukemia cell lines, indicating the importance of this tumour suppressor gene in immortalization (Wong et al., 1999) . The cell lines utilized in this study either have a deletion (CB3) or mutation (CB7) of p53. Since significant inhibition of proliferation in murine erythroleukemia cell lines was only seen for concentrations at, or in excess of 20 mM celecoxib, we examined the possibility that the status of p53 in erythroleukemia cell lines may be critical in determining the sensitivity of these cells to the drug. To examine this possibility, an F-MuLV-induced erythroleukemia cell line NKH23, which expresses wild-type p53 while exhibiting a mutation in the tumour suppressor gene p45 NFE2 was grown in the presence of various concentrations of celecoxib. Concentrations as low as 5 mM were observed to significantly effect the proliferation of these cells, while the vehicle control appeared to exhibit similar growth kinetics as non-treated cells (Po0.05) (Figure 6a ). NKH23 cells, due to their p53 wild-type status, grow considerably slower than other erythroleukemia cell lines utilized in this study. However, after multiple passages we isolated a variant of this cell line (designated NKH23-M) that appears resistant to the antiproliferative effects of celecoxib at concentrations of 5 and 10 mM (Figure 6b ). Lysates (100 mg) isolated from HB60-5 cells, stimulated with the indicated growth factors and pre-treated for 1 h with 40 mM celecoxib or EtOH control were immunoprecipitated for either c-Kit (a) or Epo-R (b) and subjected to Western blot analyses using antiphosphotyrosine 4G10 antibody. As a control, the blot was hybridized with a c-Kit antibody (a) and extract stimulated with Epo was pre-incubated for 1 h with Epo-R blocking peptide prior to the immunoprecipitation with the Epo-R antibody (b). Pre-incubation with the Epo-R blocking peptide completely inhibited the Epo-R immunoprecipitation
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We have shown that NKH23-M, similar to the erythroleukemia cell line CB7, expresses high levels of mutant form of p53, and this corresponds to little or no expression of COX-2 (Figure 7a) . However, the opposite is observed in the parental line NKH23, harbouring wild-type p53 as indicated by undetectable levels by Western analysis , which corresponds to high COX-2 expression. Similarly, parental murine erythroleukemia cell line NKH19 also expresses undetectable levels of p53 (i.e. presence of wild-type form). Once again, there appears to be significant COX-2 expression in NKH19 compared to low expression in CB3 and CB7 controls, having a p53 deletion and p53 mutation, respectively (Figure 7b ). While no mutant variants of NKH19 were isolated from this cell line, we were able to observe similar growth kinetics as NKH23 in response to 5 and 10 mM celecoxib (data not shown).
To further investigate these findings the levels of p53 protein in NKH23 cells treated with celecoxib were examined. Western blot analysis failed to detect increased stability of p53 protein in NKH23 cells treated with 5 and 10 mM concentrations of celecoxib in culture (data not shown). These results suggest that although the presence of wild-type p53 is pertinent for both the expression of COX-2 and sensitivity towards its selective inhibitor in murine erythroleukemic cells, the degree of sensitivity is independent of the expression levels of this tumour suppressor gene.
A recent study has demonstrated suppressed COX-2 expression by wild-type p53 (Subbaramaiah et al., 1999) . Interestingly, in our NKH23 and NKH19 erythroleukemia cell lines exhibiting wild-type p53, substantial increases in COX-2 protein were evident compared to the mutant p53 variant (NKH23-M). Control cell lines CB3 and CB7, both of which have acquired mutations in p53, however, express low levels of COX-2 (Figure 7a ). To further investigate these observations we examined the level of COX-2 expression in an erythroleukemia cell line expressing the murine temperature-sensitive (ts) p53
ValÀ135
. This ts protein behaves as a mutant polypeptide at 371C and as a wild-type polypeptide at 32.51C (Johnson et al., 1993) . When DP16-1 ts p53 cells were grown at 32.51C, expression levels of COX-2 decreased only slightly with respect to the parental DP16-1 cells (Figure 7c and d, respectively) . The levels of the cell cycle inhibitor, p21, known to be regulated by p53, was dramatically induced (Figure 7c ). This is in contrast with a recent report where the expression of a temperature-sensitive wild-type p53 in embryonic fibroblasts was shown to suppress COX-2 expression directly (Subbaramaiah et al., 1999 ). These observations demonstrate that in murine erythroleukemia cell lines, the presence of the wild-type p53 correlates with high expression of COX-2. We believe that the loss of p53 results in downregulation of COX-2 through an indirect mechanism involving genomic instability (see discussion). As depicted in Figure 1 , DP16-1 cells already express low levels of COX-2 and that the visible differences in these levels between the two experiments are due to differences in exposure times.
Discussion
Although the effects of NSAIDs on various types of solid tumours have been well documented, efforts have been minimal in establishing their mechanism(s) of action in hematological malignancies. In the present study, we used Friend Virus-induced erythroleukemia cell lines with defined genetic changes to examine the antileukemic effect of the COX-2 inhibitor, celecoxib. We have provided evidence for the expression of COX-2 in Friend Disease, both in leukemic splenic tissue and established cell lines, albeit at different degrees of expression. With the exception of immortalised HB60-5 cells, there appeared to be a prevalence of COX-2 in tissue over cell lines examined. This may be suggestive of increased expression in a small percentage of splenic stromal cells within the heterogeneous population at the time of sampling, over that of leukemic blasts present within the spleen. However, a more physiological explanation to these observed differences could be the status of p53 in tumours versus the cell lines. We have previously demonstrated that all primary erythroleukemias induced by Friend Virus express wild-type p53 and the loss of p53 is critical for immortalisation in culture (Wong et al., 1999) . Since we have shown a direct correlation between COX-2 expression and presence of wild-type p53 in leukemic cells, it is likely that high expression levels of COX-2 in primary tumours could reflect the status of p53 in these cells. However, we are not excluding the possibility that some levels of COX-2 expression may be associated with paracrine interactions between the splenic stroma and leukemic blasts, which could indirectly increase expression of COX-2 in leukemic cells in vivo as well. Moreover, since COX-2 expression has shown to be induced rapidly by proinflammatory mediators such as cytokines and eicosanoids (DuBois et al., 1996) , the presence of these factors, some of which may originate from the splenic stroma, could account for some increased expression in primary leukemic cells derived from splenic cultures.
With respect to HB60-5 cells, the correlation between loss of p53 and decreased COX-2 bears an exception. Establishment of the HB60-5 cell line was carried out quite differently from that of CB3 and CB7; the former having been selected in cell suspension and the latter from methylcellulose colonies. HB60-5 also represents a growth factor-dependent cell line, capable of undergoing terminal differentiation in the presence of Epo alone and Figure 7 COX-2 expression correlates with the wild-type p53 status in erythroleukemia cell lines. Total extracts were isolated from NKH23, NKH23-M, NKH19 and two erythroleukemia cell lines CB7 and CB3 that either express a mutant form of p53 or loss of the p53 gene due to gene deletion, respectively (a and b). These extracts were subjected to Western blot analysis using a p53 specific monoclonal antibody, COX-2 antibody and b-actin antibody as a loading control. Total extracts isolated from p53 temperature sensitive DP16-1 (expressing temperature-sensitive (ts) p53
ValÀ135 ) (c) and parental DP16-1 (d) grown at a density of 5 Â 10 4 cells at 32.5 and 371C, respectively, were sampled at the indicated times and subjected to Western blot analysis using antibodies to COX-2, p21 and b-actin as loading control Mechanisms of antileukemic effects by celecoxib D Cervi et al proliferating in the presence of both Epo and SCF (Tamir et al., 1999) . Both CB3 and CB7 cell lines, however, are growth factor-independent. Thus, we believe that these two groups of cell lines, although all classified as erythroleukemic, represent different timepoints within the erythropoietic lineage, therefore attributing differential gene expression capable of governing their expansion and survival in vitro. Similarly, these differences are conceivably responsible for the differential responses towards celecoxib and COX-2 expression.
To uncover the mechanism of antileukemic activity in vitro, we show that celecoxib inhibits proliferation and promotes leukemic cell death in cultured cells. Friend Virus-induced erythroleukemia cell lines (as well as two human erythroleukemia cell lines) responded to celecoxib in excess of 20 mM concentration with significant proliferative inhibition. Pro-apoptotic affects were also observed at concentrations of 40 mM and above. These results closely resemble those obtained by others who have demonstrated that selective COX-2 inhibitors result in the induction of apoptosis in various tumour models in vitro via inhibition of alternate targets. Studies pertaining to colorectal cancer clearly demonstrate that COX-2 expression can promote neoplastic progression, and inhibiting COX-2 reduces the number, size and overall polyp burden in FAP patients (Giardiello et al., 1993) . However, recent studies have also demonstrated high levels of COX-2 inhibitors to effectively inhibit the growth and behavior of tumour cell lines in culture. It is therefore conceivable that non-COX-2 targets of NSAIDs exist that can efficiently inhibit neoplastic progression. Towards identifying these targets, a recent study has demonstrated that selective COX-2 NSAIDs can interfere with a variety of intracellular pathways including the activation of the transcriptional factor NF-kB by inhibition of TNF-a signaling (Berman et al., 2002) . Moreover, dephosphorylation of PKB and decreased expression of certain members of the bcl-2 family of antiapoptotic proteins have also been identified as downstream targets of selective NSAIDs (Lin et al., 2001; Arico et al., 2002) . It is therefore likely that in Friend Virus-induced erythroleukemia COX-2 inhibitors will act similarly in COX-2-dependant and independent manners, albeit at variable concentrations. As was observed here, levels 2-10 times above physiologically achievable levels were effective in inhibiting leukemic cell growth and viability.
In this study, we have identified c-Kit and Epo-R as two new targets of selective NSAIDs, whose phosphorylation decreases dramatically in the presence of 40 mM celecoxib. This is in accordance with previous works whereby selective COX-2 inhibitors have been shown to be effective against cancer development and progression via COX-2-independent mechanisms, including alterations in the aforementioned signaling factors known to partake in cellular proliferation and apoptosis, such as NF-kB, PKB and bcl-2 (Lin et al., 2001; Berman et al., 2002; Arico et al., 2002) . Interestingly, these are also downstream factors of both c-Kit and Epo-R signaling (Bao et al., 1999; Bittorf et al., 2001; Mekori et al., 2001) , and are therefore also affected when cells expressing these receptors are treated with celecoxib. Although the tested cell line, HB60-5, does express COX-2 according to our panel analysis the concentration of drugs used in our experiments exceed those required to effectively inhibit the enzyme activity, as perceived by effective, physiologically detectable levels (Williams et al., 2000) . Thus, inhibition of COX-2 alone is not sufficient to elicit a response by these cells and therefore requires either inhibiting alternative targets alone, or simultaneously with COX-2. Nevertheless, two working hypotheses can be generated from the results presented herein: (1) celecoxib may be influencing phosphatase activity, thus leading to the dramatic down regulation of phosphorylative events and subsequent decrease in the signaling mediated by these receptors; (2) celecoxib could mediate receptor inhibition by interfering with ligand-receptor interaction extracellularly. We support the first hypothesis over the second for several reasons. In our overexpression studies, the levels of constitutively active c-Kit (HB60-5/c-Kit þ ) correlated with increased tyrosine phosphorylation in the presence of SCF and celecoxib, compared with undetectable phosphorylation in the vector (HB60-5/LXS-N) control under similar conditions. This was further associated with increased viability and growth of HB60-5/c-Kit þ cells. Thus, where celecoxib normally down regulates endogenous c-Kit activity in wild-type HB60-5 and HB60-5/LXS-N cells, as well as that of Epo-R, overexpression of active c-Kit alone provides a survival advantage for HB60-5/c-Kit þ cells. Secondly, since we have observed that celecoxib inhibits two independent receptors (c-Kit and Epo), both of which interact with specific ligands, receptor-ligand interference is highly unlikely. Thirdly, given that celecoxib is designed to act intracellularly, exhibiting extensive hydrophobic moieties, rapid influx into cells is therefore expected, where it can then be expected to interact with its targeted enzyme COX-2. In addition, with respect to our first working hypothesis, we have not entirely ruled out the other pathways potentially affected by the presence of celecoxib. Upon analysis of pan-phosphorylation conducted on lysates obtained from HB60-5 cells untreated and treated with celecoxib, marginal differences were evident between the phosphorylation patterns obtained (data not shown). As such, there indeed remains the possibility of other currently unknown targets. Nevertheless, our overexpression studies strongly elute to the c-Kit receptor signaling as being one such target.
The inhibitory effects of celecoxib on erythroleukemia cell lines in vitro can be seen at 20 mM, similar to that observed in cell lines of colorectal cancer (Williams et al., 2000) . Despite this response, considerable debate has arisen over the precise mechanism by which selective NSAIDs act in vitro and whether they recapitulate in vivo mechanisms. The first report addressing the concern of in vitro models to decipher the targets of selective COX-2 inhibitors came from Williams et al. (2000) , whereby serum levels of celecoxib, found to be far less than those administered to HCA-7 cells in vitro, were seen to have significant antitumour effects towards the HCA-7 xenograft model. We have previously demonstrated that primary cultures of erythroleukemic blasts collected from mice infected with Friend Virus cannot be established in vitro, and die rapidly. Only following serial transplantations in syngeneic mice and acquisition of appropriate genetic mutations, including inactivation of the p53 gene, can an in vitro cell line be established (Wong et al., 1999) . It is therefore plausible that the loss of this tumour suppressor gene, whose function is known to be involved in the maintenance of genomic stability (Tamir et al., 1999) , could play a role in mediating resistance of erythroleukemic cells to celecoxib in vitro. In addition, and not entirely exclusive of the aforementioned reason, since we have shown that the presence of wild-type p53 is associated with increased COX-2 expression, it may be that earlier transformed clones (i.e. primary tumours) may be sensitive to COX-2 inhibitors given that the pool of prostaglandins subsequently decreases and paracrine interactions are reduced. Following mutations in the p53 tumour suppressor, however, COX-2 levels are seen to dramatically fall, conceivably indicative of a more aggressive clone capable of expanding in a prostaglandin-independent manner. In order to examine this more closely with reference to resistance to celecoxib we have taken advantage of in-house derived erythroleukemia cell lines with defined genetic mutations. While most erythroleukemia cell lines have been shown to have mutant p53, NKH23 and NKH19 lines harbour a mutation in the tumour suppressor p45 NFE2, while maintaining wildtype p53. We observed a significant decrease in proliferative capacity of these cells at concentrations of celecoxib as low as 5 mM. To our knowledge these cells are the first reported to exhibit sensitivity to celecoxib at such a low concentration in vitro. Interestingly, acquisition of p53 mutations reverses this sensitivity thereby requiring higher concentrations of drug similar to those required for effective inhibition of other aforementioned erythroleukemia cell lines used in this study. Moreover, not only did p53 wild-type status correlate with increased sensitivity towards celecoxib, but also with a significant increase in the expression of COX-2 in both NKH23 and NKH19 cells. Given these observations were made in an in vitro setting suggests a p53-mediated response mechanism involved with prostaglandin signaling, which is apparently disabled in their mutated p53 counterpart cells. Further investigations are currently being conducted to elucidate this mechanism. Hence, these results suggest that the sensitivity to the selective COX-2 inhibitors is p53 dependent and our results suggest that a higher dose of celecoxib is likely required to inhibit the growth of the p53 negative erythroleukemic cells via COX-2-independent mechanisms.
A recent report demonstrated that p53 suppresses COX-2 expression in embryo fibroblasts through competition with the TATA-binding protein (Subbaramaiah et al., 1999) . In contrast, in our leukemic system, we have detected high levels of COX-2 expression in Friend Virus-induced primary erythroleukemic cells as well as two erythroleukemia cell lines that express wildtype-p53. We have shown that the acquisition of mutant p53 in two of these lines resulted in low-level expression of COX-2. Previous studies in our laboratory have demonstrated that while loss of p53 is critical for in vitro establishment of erythroleukemia cell lines, it is not sufficient to confer immortality (Wong et al., 1999) . These studies raised the possibility that the induction of genomic instability as a consequence of p53 loss likely alters a spectrum of gene expression that is necessary for immortalisation in culture. It is therefore possible that the acquisition of genetic changes during the in vitro phase of immortalization, initiated by loss p53, may result in a drastic downregulation of COX-2 expression leading to celecoxib resistance. Thus, it is possible that while primary erythroleukemic cells are intrinsically sensitive to celecoxib, downregulation of COX-2 due to the indirect effects of the p53 loss in these cells may increase their tolerance to celecoxib in vitro. The precise mechanism of this increased resistance to celecoxib in the absence of wild-type p53 remains elusive.
In summary, we have provided evidence to support the expression of COX-2 in Friend Virus-transformed erythroleukemic cells. We have shown that celecoxib is capable of suppressing proliferation and inducing apoptosis in erythroleukemic cells in culture. We have provided evidence for the first time that celecoxib at high doses is sufficient to elicit apoptosis via inhibition of both the c-Kit and Epo-receptors, and that these suppressive effects may be partially reversed in the presence of overexpressing active c-Kit. Furthermore, we have shown that the genetic background of murine erythroleukemic cells, illustrated by p53 status, may determine the level of resistance to celecoxib. Overall, these results provide important insight into the mechanism of action of celecoxib in erythroleukemic cells along with pertinent evidence that acquired genetic mutations in p53, and potentially receptor activity, can facilitate their resistance towards selective NSAIDs.
Materials and methods
Cox-2 inhibitors
Cox-2 inhibitor celecoxib, SC-58635, was provided by Monsanto in powder form and reconstituted to a 20 mM stock solution in 95% ethanol from which appropriate volumes were taken and added to cell cultures for in vitro analysis.
Splenic tumour tissues and HB60-5 cell line culturing conditions
Splenic tumours 12F, FVP-12 and HB26-4b were derived from moribund BALB/c mice infected with one of two different forms of Friend Virus, Friend Virus-Polycythemia (FVP) and Friend-Murine Leukemia Virus (F-MuLV) as previously described (Shibuya and Mak, 1983 ) and stored at À701C until analysed. Erythroleukemia HB60-5 cell line was generated from a primary erythroleukemia cell suspension isolated from moribund BALB/c mice infected with clone 57 of F-MuLV helper virus at birth, as previously described (Tamir et al., 1999) . NKH23 cell line was derived from erythroleukemias induced by F-MuLV in p45 NFE2 deficient mice . NKH23-M is a derivative of NKH23 that was passaged for over two months in culture. NKH23, NKH23-M and HB60-5 cells were maintained in alpha minimum essential medium (aMEM) 10% fetal bovine serum (FBS) (Gibco), 0.1 U/ml erythropoietin (Epo) (Sigma), 10 mg/ml stem-cellfactor (SCF) and 100 U/ml Penicillin-Streptomycin. Murine and human erythroleukemia cell lines were maintained in a-MEM supplemented with 10% FBS.
Proliferation assay
Unless indicated otherwise, erythroleukemic HB60-5 cells were cultured at 5 Â 10 4 cells/ml in 10 ml of medium, containing 40 mM celecoxib or volume equivalent of 95% ethanol vehicle. Cells were allowed to grow over a period of 72 h during which time cell counts and viability were assessed every 24 h by trypan blue (Gibco) exclusion utilizing a hemocytometer.
Apoptosis assay
Induction of apoptosis of the erythroleukemia cell lines HB60-5, K562 and Hel by celecoxib was determined by DNA laddering pattern. Cells were grown in the absence or presence of 40, 50 and 60 mM celecoxib drug, or equivalent volume of ethanol vehicle for a 48 h period, followed by harvesting and washing twice in 1 Â phosphate buffered saline (PBS) and resuspending in a 1 : 1 volume of Solution A (200 mM NaCl, 40 mM Tris pH ¼ 7.5 and 20 mM EDTA pH ¼ 8.0) and Solution B (1% SDS) with the addition of 20 mL Proteinase K. The resuspension was incubated overnight at 571C. Samples were then loaded and separated on a 2% agarose gel and stained with ethidium bromide.
Infection of HB60-5 cells with retroviral vectors c-Kit þ and LXS-N control
Packaging GP þ E-86 cells producing viral constructs with mutant Kit (constitutive active, c-Kit þ ) and LXS-N (control vector) were kind gifts provided by Dr R. Rottapel and were the sources of retroviruses used in this study. Briefly, cells were grown in p-MEM medium (Gibco) containing 10% FBS (Gemini Bio-Products) to approximately 30-40% confluency (assessed visually), after which, the medium was replaced with fresh, conditioned HB60-5-containing medium (p-MEM, FBS 10%, Epo 1 U/ml, and SCF 100 ng/mL) and co-cultured for 48 h at 371C and 5% CO 2 . The HB60-5 suspension layer was than carefully removed, pelleted and resuspended in fresh, conditioned p-MEM for a period of 24 h. Neomycin positive clones were then seletected over the next 7-10 days until established and maintainable in p-MEM, 10% FBS, Epo 1 U/ ml, SCF 100 ng/ml.
Western blot analysis and immunoprecipitation
Erythroleukemic cells harvested from culture were washed twice in 1 Â PBS and lysed in RIPA buffer (0.5% NP-40, 50 mM Tris HCl, pH 8.0, 120 mM NaCl, 50 mM NaF, 10 mM aprotinin, 100 mg/ml leupeptin and 10 mM phenylmethylsufonyl fluoride) at 41C and centrifuged at 14 000 g for 10 min at room temperature. Leukemic tissues collected from spleens were homogenized to a single cell suspension in 1 Â PBS and larger fragments were allowed to sediment. Single cell suspensions were then further washed in 1 Â PBS and subjected to the same procedure above. For Western blotting, 20 mg of cell lysates were resolved on a 12% SDS-polyacrylamide gel and immunoblotted as described (Howard et al., 1996) . Antibody to COX-2 was obtained from Santa Cruz, 240 monoclonal antibody for p53 was generously provided by Dr S. Benchimol and utilized according to previously described methods (Munroe et al., 1990) . Given its specificity for mutant p53, this antibody does not cross-react with the wild-type form, nor will it react with peptide-lysates derived from cells with deleted p53. The antibody against murine b-actin was purchased from Sigma. Development of the membranes took place in 1 : 1 ratio of Luminol/Enhancer solution (Pierce) and stable peroxide solution (Pierce) followed by autoradiography.
For immunoprecipitations (IPs), cells were starved for 9 h in aMEM þ 0.5% FBS. Prior to induction with Epo or SCF cells were incubated for 1 hin the presence of 40 mM celecoxib or volume equivalent of EtOH. Cells were then stimulated with Epo (1.0 U/ml) or SCF (100 ng/ml) for 10 min at 371C, collected by centrifugation, washed with cold PBS and lysed in RIPA buffer as previously described (Howard et al., 1996) . Protein quantification and sample preparation followed as above. After pre-clearing with Protein-A sepharose, 200 mg of lysates were used in IPs and subjected to Western blotting. Antibodies for c-Kit and Epo-R were obtained from Santa Cruz and antiphosphotyrosine antibody 4G10 from Upstate Biotechnology.
Data statistical analysis
Comparison of growth kinetics within a given experiment was conducted using repeated Student's t-Test for one and two populations with significance values of Po0.05. One-way ANOVAs were conducted in similar fashion with significance values of Po0.05.
